On July 16, 2020 Shanghai Junshi Biosciences reported that it has completed a $692 million IPO on the Shanghai STAR Board, becoming the first biopharma to have a dual listing on the Hong Kong and STAR Exchanges (Press release, Shanghai Junshi Bioscience, JUL 16, 2020, View Source [SID1234561961]). Junshi staged a $394 million Hong Kong IPO in late 2018, about the same time the company’s Tuoyi became the first China-developed anti-PD-1 approved for China use. Benefiting from strong demand, Junshi significantly increased the size of its STAR debut offering from an original $400 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!